Anavex Life Sciences has announced the completion of scale-up manufacturing of Anavex 2-73, its lead compound for the treatment of Alzheimer's disease.
Dr Herve de Kergrohen, chief executive officer of Anavex, said: 'This lead drug candidate shows potential to alter the course of Alzheimer's disease by using sigma receptors to correct dysfunction in the mitochondria and ultimately protect cells from oxidative stress, which is believed to be an underlying cause of the disease.' Anavex will shortly announce the selection of the Contract Research Organisation in charge of carrying out its Phase I clinical trials.
Phase I is the stage at which testing moves to humans.
Trials are designed to confirm the drug's safety and determine its tolerability in humans.
Pharmacokinetics (the mechanisms of absorption and distribution of the drug, the rate at which a drug begins to act and the duration of its effect, as well as chemical changes of the substance in the body) and pharmacodynamics (physiological effects of drugs on the body, mechanisms of action and relationship between drug concentration and effect) are also studied during Phase I.
Anavex 2-73 has demonstrated powerful neuroprotective, anti-amnesic, anti-convulsive and anti-depressive activity in animal models.
It also exhibited an excellent safety profile and therapeutic activity at very low doses.
Syntagon developed a five-step synthetic procedure that achieved excellent yields in terms of the quantity of the compound that was produced and delivered it to Anavex on time.
In addition, all analytical methods were evaluated and developed at Syntagon.
